Briefing — August '02
They managed, within
the first 100 words or so of their July 18th letter to those of
us on the Enbrel waiting list, to blame it on the FDA.
They’re building this “state-of-the-art biologic manufacturing
facility in Rhode Island” to double production capacity for Enbrel —
which, evidently, is a requirement before those of us who signed up for
the new drug will get it — and now they are “working diligently to
gain FDA approval of this facility as quickly as possible.”
Well, they may think
they have snagged me. As far
as I’m concerned it’s a race: Amevive
(Biogen) or Enbrel (Immunex). Enbrel
or Amevive. If Biogen’s new
biologic, Amevive (alefacept) hits the streets before Immunex gets their
new plant burping out product, I won’t hesitate to try Amevive, first.
And, of course, if it works I might not ever get ‘round to
Enbrel. Treats
in the Mail Bag The first three
exchanges in this month’s mail have to do with Soriatane, Amevive and
Enbrel, in that order. Jeffrey
M. is trying to make sense of the pressure he’s feeling to start using
Soriatane.... We asked for and have received a glowing report from an
Amevive trial subject (he makes this stuff sound awfully good).... But
Mike M. makes Enbrel sound sweet, too.... Dave W. sounds off
some more about diets and has good remarks for these correspondents in
last month's mail:
Fred, Dian, Rachel and Vix. New
Poetry New poet debuting in
Flaker Creativity this month. Please
read Sharee’s poem, Psoriatic Cry. ***** With a little luck, I will survive the NPF 2002 conference in Orlando this coming weekend (Aug 9-11) and be back in September with pics and tales to tell! -Ed
www.flakehq.com |